Q4 2024 Microbix Biosystems Inc Earnings Call Transcript
Key Points
- Microbix Biosystems Inc (MBXBF) achieved a 40% revenue growth in fiscal 2024, reaching the upper range of their target growth rate of 20% to 40%.
- The company reported record revenues of $6.3 million in Q4, marking a 48% increase from the previous year.
- Both the antigens and CAPS businesses experienced significant growth, with antigens up 50% and CAPS up 42% in Q4.
- Microbix Biosystems Inc (MBXBF) maintained strong operational control, achieving positive EBITDA, net earnings, and cash flow while actively repurchasing shares.
- The company is expanding its market reach, acquiring new customers in North America, the EU, and Asia, and is committed to maintaining a compound annual growth rate of 20% to 40%.
- The company faces potential risks from US tariffs, which could impact their business and future growth prospects.
- There is no specific guidance provided for gross margins in 2025, with expectations only set at a target of around 60%.
- The company acknowledges the need for continued investment in infrastructure and SG&A, which may offset operating leverage.
- Microbix Biosystems Inc (MBXBF) has not seen significant changes in its board of directors, raising concerns about the need for new perspectives.
- The company is cautious about telegraphing its moves in oncology and genetic testing, which may limit transparency for investors.
(audio in-progress) numbers this morning. So make sure to check those out. This session will deal specifically with those earnings or that earnings release rather. With me today, I have Cameron Groome, President and CEO; Ken Hughes, COO; and Jim Currie, CFO. As always, this presentation will contain forward-looking statements. If you'd like to know more about those, you can find them on the presentation on the company's website, which will be updated today. And there will be a Q&A session, so feel free to enter your questions in the Q&A box, or you can send them directly to me.
With that out of the way, thanks, gentlemen, for joining me this morning.
Morning, Deborah.
Pleasure, Deborah.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
